Payden & Rygel Raised By $2.02 Million Its Magellan Midstream Partners (MMP) Position; Amphastar Pharmaceuticals (AMPH) Shorts Lowered By 3.83%

June 24, 2018 - By Dolores Ford

Payden & Rygel increased Magellan Midstream Partners (MMP) stake by 8.83% reported in 2018Q1 SEC filing. Payden & Rygel acquired 34,750 shares as Magellan Midstream Partners (MMP)’s stock rose 5.46%. The Payden & Rygel holds 428,150 shares with $24.98M value, up from 393,400 last quarter. Magellan Midstream Partners now has $15.89B valuation. The stock increased 1.15% or $0.79 during the last trading session, reaching $69.65. About 890,682 shares traded. Magellan Midstream Partners, L.P. (NYSE:MMP) has declined 7.22% since June 24, 2017 and is downtrending. It has underperformed by 19.79% the S&P500. Some Historical MMP News: 29/05/2018 – Steve Madden Selects MMP’s INCITE Platform to “Step-Up” Empowerment of Front Line Associates & Impact the In-Store Experience; 03/05/2018 – Magellan Midstream Sees 2Q EPS 95c; 20/04/2018 – DJ Magellan Midstream Partners LP, Inst Holders, 1Q 2018 (MMP); 03/05/2018 – MAGELLAN MIDSTREAM PARTNERS LP – INCREASES ANNUAL GUIDANCE FOR 2018 DISTRIBUTABLE CASH FLOW TO $1.08 BLN; 21/05/2018 – MAGELLAN MIDSTREAM PARTNERS LP – MAGELLAN CURRENTLY EXPECTS TO SPEND ABOUT $300 MLN ON PROJECT; 12/04/2018 – BridgeTex crude pipeline cancels low spot rate as demand rises; 09/04/2018 – MAGELLAN MIDSTREAM PARTNERS LP MMP.N : RBC RAISES TO OUTPERFORM FROM SECTOR PERFORM; 02/05/2018 – Magellan Midstream Increases Scope and Extends Open Season for Potential Expansion of Western Leg of Texas Refined Products Pip; 20/04/2018 – Insur Dept (RI): MMP Notice 2018-1: Medical Marijuana Personal Grow “Plant Tag Certificate” – 4/20/2018; 21/05/2018 – Magellan Midstream to Expand Western Leg of Texas Refined Petroleum Products Pipeline System

Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) had a decrease of 3.83% in short interest. AMPH’s SI was 1.46M shares in June as released by FINRA. Its down 3.83% from 1.51 million shares previously. With 219,300 avg volume, 7 days are for Amphastar Pharmaceuticals Inc (NASDAQ:AMPH)’s short sellers to cover AMPH’s short positions. The SI to Amphastar Pharmaceuticals Inc’s float is 4.19%. The stock decreased 2.05% or $0.33 during the last trading session, reaching $15.77. About 179,830 shares traded. Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) has risen 3.43% since June 24, 2017 and is uptrending. It has underperformed by 9.14% the S&P500. Some Historical AMPH News: 14/05/2018 – Amphastar Pharmaceuticals Receives FDA Approval for Calcium Chloride Injection; 21/03/2018 – AMPHASTAR SAYS COURT AFFIRMED JURY VERDICT FROM JULY 21, 2017; 21/03/2018 – AMPHASTAR PHARMACEUTICALS INC – DISTRICT COURT PROVIDED A SCHEDULE FOR ANTITRUST LAWSUIT WITH A JURY TRIAL SET FOR SEPTEMBER 9, 2019; 21/03/2018 – AMPHASTAR PHARMACEUTICALS INC – ON MARCH 20, DISTRICT COURT DENIED MOMENTA’S & SANDOZ’S MOTION TO DISMISS AMPHASTAR’S “ANTITRUST” LAWSUIT; 02/05/2018 – Amphastar Closes Below 50-Day Moving Average: Technicals; 21/03/2018 – AMPHASTAR REPORTS FINAL JUDGMENT IN PATENT LITIGATION VS MOMENT; 09/05/2018 – Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2018; 12/03/2018 – Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Fiscal Year Ended December 31, 2017; 21/03/2018 – Amphastar: Ruled ‘Prevailing Party’ in Patent Litigation Against Momenta Pharmaceuticals and Sandoz; 14/05/2018 – AMPHASTAR GETS FDA APPROVAL FOR CALCIUM CHLORIDE INJECTION

Amphastar Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development, manufacture, marketing, and sale of generic and proprietary injectable, inhalation, and intranasal products. The company has market cap of $735.10 million. It operates in two divisions, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients. It currently has negative earnings. The companyÂ’s product portfolio comprises enoxaparin, a low molecular weight heparin that is used as an anticoagulant for prevention and treatment of deep vein thrombosis; naloxone for treating opioid overdose; Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency; Amphadase, a bovine-sourced hyaluronidase injection for the dispersion and absorption of other injected drugs; and lidocaine jelly, a local anesthetic product for urological procedures.

More important recent Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) news were published by: Globenewswire.com which released: “Amphastar Announces Approval for Isoproterenol Hydrochloride Injection, USP” on June 19, 2018, also Seekingalpha.com published article titled: “FDA approves Amphastar’s ANDA for Isoproterenol Hydrochloride Injection, USP”, Globenewswire.com published: “Amphastar Pharmaceuticals to Present at the Jefferies Healthcare Conference 2018” on June 04, 2018. More interesting news about Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) was released by: Globenewswire.com and their article: “Consolidated Research: 2018 Summary Expectations for Summit Therapeutics, Orbotech, Amphastar Pharmaceuticals …” with publication date: June 05, 2018.

Investors sentiment increased to 1.45 in 2018 Q1. Its up 0.30, from 1.15 in 2017Q4. It increased, as 9 investors sold Amphastar Pharmaceuticals, Inc. shares while 31 reduced holdings. 20 funds opened positions while 38 raised stakes. 20.28 million shares or 0.00% less from 20.28 million shares in 2017Q4 were reported. Connecticut-based Aqr Cap Mgmt Limited Co has invested 0% in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH). Moreover, Parametric Port Assocs Ltd has 0% invested in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) for 75,132 shares. Renaissance Tech Ltd Com holds 51,600 shares or 0% of its portfolio. Public Sector Pension Invest Board stated it has 0% in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH). Citigroup holds 0% or 103,919 shares. 414,388 are held by Bankshares Of New York Mellon. Cadence Capital Management reported 0.03% stake. The Georgia-based Invesco has invested 0.01% in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH). Nordea Ab invested in 167,671 shares or 0.01% of the stock. Millennium Mgmt Ltd Liability Corporation invested in 0% or 43,626 shares. The New Jersey-based Prudential Fincl Inc has invested 0% in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH). Moreover, Dimensional Fund Advisors Lp has 0.01% invested in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) for 1.69 million shares. City Holdings invested in 0% or 400 shares. 182,749 were accumulated by Schwab Charles Investment Mgmt Inc. Loomis Sayles & Ltd Partnership has 0% invested in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH).

Among 6 analysts covering Amphastar Pharmaceuticals (NASDAQ:AMPH), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Amphastar Pharmaceuticals had 28 analyst reports since August 10, 2015 according to SRatingsIntel. Jefferies maintained the shares of AMPH in report on Thursday, November 9 with “Buy” rating. Zacks upgraded the shares of AMPH in report on Tuesday, August 18 to “Hold” rating. As per Friday, August 11, the company rating was maintained by Jefferies. The firm has “Hold” rating by BMO Capital Markets given on Thursday, October 26. Piper Jaffray maintained Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) rating on Friday, September 15. Piper Jaffray has “Buy” rating and $19.0 target. Piper Jaffray maintained Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) rating on Wednesday, August 9. Piper Jaffray has “Buy” rating and $1900 target. The rating was maintained by Piper Jaffray on Friday, October 20 with “Buy”. The stock has “Market Perform” rating by BMO Capital Markets on Friday, November 10. The stock of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) earned “Buy” rating by Jefferies on Friday, October 27. On Friday, February 19 the stock rating was initiated by Wells Fargo with “Outperform”.

Since February 12, 2018, it had 0 buys, and 1 sale for $1.51 million activity. 22,251 Magellan Midstream Partners, L.P. (NYSE:MMP) shares with value of $1.51 million were sold by MEARS MICHAEL N.

More notable recent Magellan Midstream Partners, L.P. (NYSE:MMP) news were published by: Fool.com which released: “1 High-Yielding MLP That Continues Doing Things the Right Way” on June 06, 2018, also Nasdaq.com with their article: “Better Buy: Enterprise Products Partners LP vs. Magellan Midstream Partners, LP” published on June 21, 2018, Seekingalpha.com published: “Boston Scientific Is A Good Earnings Story – Cramer’s Lightning Round (6/13/18)” on June 14, 2018. More interesting news about Magellan Midstream Partners, L.P. (NYSE:MMP) were released by: Fool.com and their article: “This High-Yield Dividend Stock Is in a Class of Its Own” published on June 17, 2018 as well as Seekingalpha.com‘s news article titled: “Energy Transfer Partners restores power to West Texas facility” with publication date: June 08, 2018.

Payden & Rygel decreased At&T (NYSE:T) stake by 11,200 shares to 338,200 valued at $12.06M in 2018Q1. It also reduced Crown Castle Intl Corp (NYSE:CCI) stake by 3,020 shares and now owns 120,980 shares. Home Depot (NYSE:HD) was reduced too.

Investors sentiment increased to 0.78 in 2018 Q1. Its up 0.02, from 0.76 in 2017Q4. It increased, as 48 investors sold MMP shares while 175 reduced holdings. 42 funds opened positions while 131 raised stakes. 135.98 million shares or 1.03% more from 134.60 million shares in 2017Q4 were reported. Westwood Holdings Gru holds 1.18 million shares. Financial Advisers Limited Liability stated it has 0.09% of its portfolio in Magellan Midstream Partners, L.P. (NYSE:MMP). Thompson Siegel & Walmsley Limited Com invested in 0% or 3,457 shares. Hm Payson & reported 3,602 shares or 0.01% of all its holdings. 28,582 are held by Bnp Paribas Arbitrage Sa. Narwhal Management owns 29,350 shares. Mariner Wealth Advisors has 61,580 shares for 0.22% of their portfolio. Segment Wealth Mgmt Limited Liability Corporation has invested 0.4% in Magellan Midstream Partners, L.P. (NYSE:MMP). Essex Service holds 0.06% or 5,481 shares. Hudock Limited Com holds 0% of its portfolio in Magellan Midstream Partners, L.P. (NYSE:MMP) for 12 shares. Exane Derivatives stated it has 15 shares or 0% of all its holdings. Coastline Comm accumulated 22,300 shares. Cypress Group holds 0.58% in Magellan Midstream Partners, L.P. (NYSE:MMP) or 47,175 shares. 31,035 are owned by Suntrust Banks Inc. Carnegie Asset Mgmt Limited Co holds 37,705 shares.

Magellan Midstream Partners, L.P. (NYSE:MMP) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: